美国 · SEC FORM 4
SpyGlass Pharma, Inc.
SGP · Nasdaq · CIK 0001778922 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-02-09 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. · $59.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-02-09 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M..
近期 Form 4 活动
17买入
0卖出
53其他 Form 4 交易行
15SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,253,724
- 上期报告
- 1,229,711
- 日均成交量
- 176,358
- 回补天数
- 7.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Yang Rick | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Walker Paul Edward | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | SANDELL SCOTT D | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Pardo Geoffrey B | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2026-02-09 | NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Mathers Edward T | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Makhzoumi Mohamad | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,690,000 | USD 16.00 | USD 59,040,000 | SEC 申报 ↗ |
| 2026-02-09 | Khan Bilal Arshad | 买入 (P) | Common Stock | 135,000 | USD 16.00 | USD 2,160,000 | SEC 申报 ↗ |
| 2026-02-09 | Florence Anthony A. Jr. | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Chang Carmen | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Behbahani Ali | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | BASKETT FOREST | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Nielsen Kirk G. | 买入 (P) | Common Stock | 165,000 | USD 16.00 | USD 2,640,000 | SEC 申报 ↗ |
| 2026-02-09 | Klein Peter Justin; Nielsen Kirk G.; Vensana Capital I GP, LLC; Vensana Capital I, L.P. | 买入 (P) | Common Stock | 165,000 | USD 16.00 | USD 2,640,000 | SEC 申报 ↗ |
Form 4 申报证据
70 transaction lines in the latest 365-day window; 70 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Yang Rick | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Yang Rick | C (C) | Common Stock | 3,727,370 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Walker Paul Edward | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (29 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Yang Rick | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Yang Rick | C (C) | Common Stock | 3,727,370 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Walker Paul Edward | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Walker Paul Edward | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | SANDELL SCOTT D | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | SANDELL SCOTT D | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Pardo Geoffrey B | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Pardo Geoffrey B | C (C) | Common Stock | 1,875,013 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | C (C) | Common Stock | 3,727,370 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Mathers Edward T | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Mathers Edward T | C (C) | Common Stock | 3,727,370 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Makhzoumi Mohamad | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Makhzoumi Mohamad | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,690,000 | USD 16.00 | USD 59,040,000 | SEC 申报 ↗ |
| 2026-02-09 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | C (C) | Common Stock | 4,331,117 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Khan Bilal Arshad | 买入 (P) | Common Stock | 135,000 | USD 16.00 | USD 2,160,000 | SEC 申报 ↗ |
| 2026-02-09 | Florence Anthony A. Jr. | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Florence Anthony A. Jr. | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Chang Carmen | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Chang Carmen | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Behbahani Ali | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | Behbahani Ali | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | BASKETT FOREST | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-09 | BASKETT FOREST | C (C) | Common Stock | 5,084,633 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Nielsen Kirk G. | 买入 (P) | Common Stock | 165,000 | USD 16.00 | USD 2,640,000 | SEC 申报 ↗ |
| 2026-02-09 | Nielsen Kirk G. | C (C) | Common Stock | 2,597,552 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Klein Peter Justin; Nielsen Kirk G.; Vensana Capital I GP, LLC; Vensana Capital I, L.P. | 买入 (P) | Common Stock | 165,000 | USD 16.00 | USD 2,640,000 | SEC 申报 ↗ |
| 2026-02-09 | Klein Peter Justin; Nielsen Kirk G.; Vensana Capital I GP, LLC; Vensana Capital I, L.P. | C (C) | Common Stock | 2,597,552 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SGP |
| CIK | 0001778922 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 70 transaction lines from 2026-02-09 to 2026-02-09 17 P purchase lines · 0 S sale lines · 53 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.